HERCULES, Calif. —Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two products for the Droplet Digital PCR (ddPCR) platforms. The ddPCR Assays for AAV Viral Titer and the Vericheck ddPCR Mycoplasma Detection Kit support the development and manufacture of safe and effective cell and gene therapies.
Accurate quantification of gene therapies is critical for safe and effective patient dosing. Bio Rad's sensitive ddPCR Assays for AAV Viral Titer run on the company's QX200 Droplet Digital PCR System or the QX ONE Droplet Digital PCR System deliver an accurate and absolute count of the adeno-associated virus (AAV) vector in a sample. The assays are available on the "Droplet Digital PCR Assays" area of Bio-Rad's website, where customers can purchase off-the-shelf assays for common viral vectors and plasmids used in gene therapies. They can also generate a new custom design for their gene of interest in minutes.
Gene therapies are inherently at risk of contamination from Mycoplasma, a pathogenic genus of bacteria, during the production process and therefore must be carefully monitored to ensure contaminants are not present in the final product. Bio-Rad's Vericheck ddPCR Mycoplasma Detection Kit runs on the company's ddPCR platforms to deliver accurate results with significantly fewer false positives compared to quantitative PCR methods.
"The expansion of our ddPCR product portfolio in the cell and gene therapy space reflects our overall commitment to addressing the global need for safe and effective therapeutics," said Simon May, PhD, Bio-Rad SVP and General Manager, Digital Biology Group. "As cell and gene therapies move forward in greater numbers, we will provide our expertise and leadership in digital PCR, offering industry-tailored solutions that simplify product development and manufacturing processes," he added.
Please visit bio-rad.com/ddPCR-CellAndGeneTherapy to learn more about Bio-Rad's portfolio of ddPCR cell and gene therapy products.
BIO-RAD, DDPCR, DROPLET DIGITAL PCR, and QX ONE are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products, our overall commitment to addressing the global need for safe and effective therapeutics, and that we will provide our expertise and leadership in digital PCR and offer the industry tailored solutions that simplify product development and manufacturing processes. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.